அறிவியல் இடைமுகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from அறிவியல் இடைமுகம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In அறிவியல் இடைமுகம் Today - Breaking & Trending Today

Why some melanoma patients do not respond to immunotherapy

E-Mail
NEW YORK, NY (March 1, 2021) By harnessing the immune system against cancer, immunotherapies have revolutionized the way some types of cancer are treated. But most patients across cancer types do not respond, and in most cases, scientists are at a loss as to why.
Researchers at Columbia and MIT have created a new technique that can uncover nearly all of the tricks cancer cells use to evade immunotherapies, which could lead to the development of more effective treatments.
The researchers tested their new technique with cancer cells and matching immune cells from melanoma patients and identified previously unknown resistance mechanisms to immune checkpoint inhibitors, a powerful and widely used class of immunotherapy drugs. ....

Adriennem Luoma Dana Farber , Chantale Bernatchez , Dirk Schadendorf , Benjamin Izar , Shruti Malu Dana Farber , Pratikshai Thakore , Michaels Cuoco , Johannesc Melms , Aviv Regev , Louisv Gerstner Jr , Brian Cleary , Brucee Johnson , Maryann Zhao , Asaf Rotem , Chrisj Frangieh , Lila Hovey , Dana Farber , Wendy Schmidt , German Cancer Consortium , Koch Institute , Md Anderson Cancer Center , University Hospital Essen , Velocity Fellow Program , Scholars Program , Dana Farber Cancer Institute , Burroughs Wellcome Fund Career Award ,

New screening platform leads to discovery of next-generation prodrugs for type 1 diabetes

E-Mail
With nearly 2 million Americans battling type 1 diabetes, it is no surprise that clinical therapies for the disease are constantly evolving and improving. In type 1 diabetes mellitus, the body s immune system attacks and destroys insulin-producing β-cells. As a result, people living with type 1 diabetes lose insulin secretion and encounter difficulty regulating glucose levels especially after meals. Drugs developed to proliferate β-cells often are inefficient and have off-target effects that can dysregulate other cell types and pancreatic hormone production. To address these issues, researchers at Brigham and Women s Hospital and the Broad Institute teamed up to design next-generation β-cell-targeting proliferators: zinc-binding prodrugs (ZnPD). To achieve this, the researchers engineered a new screening platform, the Disque Platform, to better represent β-cells in the lab. Utilizing the Disque Platform, researchers identified a ZnPD drug which exhibited a 2.4-f ....

United States , Peter Jones , Amit Choudhary , Jeff Karp , Kisuk Yang , Brigham Department Of Anesthesiology , Broad Institute , Consortium On Human Islet Biomimetics , Harvard Stem Cell Institute , Burroughs Wellcome Fund Career Award , Karp Lab , Disque Platform , Renal Medicine , Perioperative Pain , Burroughs Wellcome Fund , Career Award , Scientific Interface , National Institutes , Human Islet Research Network Consortium , Human Islet Biomimetics , Harvard Stem Cell , Frequency Therapeutics , ஒன்றுபட்டது மாநிலங்களில் , பீட்டர் ஜோன்ஸ் , அமித் சவுத்ரி , ஜெஃப் கார்ப் ,